Literature DB >> 28580636

Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.

Paolo Strati1, Sameer A Parikh1, Kari G Chaffee1, Neil E Kay1, Timothy G Call1, Sara J Achenbach1, James R Cerhan1, Susan L Slager1, Tait D Shanafelt1.   

Abstract

The ultimate cause of death for most patients with newly diagnosed chronic lymphocytic leukaemia (CLL) and its relationship to co-morbid health conditions is poorly defined. We conducted a prospective cohort study that systematically followed 1143 patients diagnosed with CLL between June 2002 and November 2014. Comorbid health conditions at the time of CLL diagnosis and their relationship to survival and cause of death were evaluated. Collectively, 1061 (93%) patients had at least one co-morbid health condition at the time of CLL diagnosis (median number 3). Despite this, 89% of patients had a low-intermediate Charlson Comorbidity Index score (CCI) at diagnosis. After a median follow-up of 6 years, 225 patients have died. Death was due to CLL progression in 85 (46%) patients, infection in 14 (8%) patients, other cancer in 35 (19%) patients and comorbid health conditions in 50 (27%) patients. Higher CCI score and a greater number of major comorbid health conditions at the time of CLL diagnosis was associated with shorter non-CLL specific survival, but not with shorter CLL-specific survival on multivariate analysis. In conclusion, CLL and CLL-related complications (infections and second cancers) are the overwhelming cause of death in patients with CLL, regardless of CCI score and number of comorbid health conditions at diagnosis.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  causes of death; chronic lymphocytic leukaemia; comorbidities

Mesh:

Year:  2017        PMID: 28580636      PMCID: PMC6377071          DOI: 10.1111/bjh.14785

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

2.  Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia.

Authors:  Paul Thurmes; Timothy Call; Susan Slager; Clive Zent; Gregory Jenkins; Susan Schwager; Deborah Bowen; Neil Kay; Tait Shanafelt
Journal:  Leuk Lymphoma       Date:  2008-01

3.  Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Matthew T Drake; Matthew J Maurer; Cristine Allmer; Kari G Rabe; Susan L Slager; George J Weiner; Timothy G Call; Brian K Link; Clive S Zent; Neil E Kay; Curtis A Hanson; Thomas E Witzig; James R Cerhan
Journal:  Blood       Date:  2010-11-03       Impact factor: 22.113

4.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

5.  Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Kari G Rabe; Neil E Kay; Clive S Zent; Diane F Jelinek; Megan S Reinalda; Susan M Schwager; Debbie A Bowen; Susan L Slager; Curtis A Hanson; Timothy G Call
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

6.  Cholesterol esters as growth regulators of lymphocytic leukaemia cells.

Authors:  M F Mulas; C Abete; D Pulisci; A Pani; B Massidda; S Dessì; A Mandas
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

7.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

8.  Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

Authors:  William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Charles Koller; Miloslav Beran; Francis Giles; Farhad Ravandi; Susan Lerner; Hagop Kantarjian; Michael Keating
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

9.  Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Apostolia-Maria Tsimberidou; Sijin Wen; Peter McLaughlin; Susan O'Brien; William G Wierda; Susan Lerner; Sara Strom; Emil J Freireich; L Jeffrey Medeiros; Hagop M Kantarjian; Michael J Keating
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

10.  Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study.

Authors:  J A Royle; P D Baade; D Joske; J Girschik; L Fritschi
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

View more
  22 in total

1.  Ethnic and geographic diversity of chronic lymphocytic leukaemia.

Authors:  Shenmiao Yang; Abraham M Varghese; Nitin Sood; Carlos Chiattone; Norah O Akinola; Xiaojun Huang; Robert Peter Gale
Journal:  Leukemia       Date:  2020-10-19       Impact factor: 11.528

Review 2.  Targeting BTK in CLL: Beyond Ibrutinib.

Authors:  David A Bond; Jennifer A Woyach
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

3.  Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death.

Authors:  Emelie Curovic Rotbain; Carsten Utoft Niemann; Klaus Rostgaard; Caspar da Cunha-Bang; Henrik Hjalgrim; Henrik Frederiksen
Journal:  Leukemia       Date:  2021-02-18       Impact factor: 11.528

4.  Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients.

Authors:  Namrata Singh; Sarah L Mott; Grerk Sutamtewagul; Ashley McCarthy; Susan L Slager; James R Cerhan; Zuhair Ballas; Brian K Link
Journal:  EJHaem       Date:  2020-09-01

Review 5.  Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach.

Authors:  Paolo Strati; Alessandra Ferrajoli
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

6.  Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.

Authors:  H Parry; G McIlroy; R Bruton; M Ali; C Stephens; S Damery; A Otter; T McSkeane; H Rolfe; S Faustini; N Wall; P Hillmen; G Pratt; S Paneesha; J Zuo; A Richter; P Moss
Journal:  Blood Cancer J       Date:  2021-07-30       Impact factor: 11.037

7.  Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.

Authors:  AnnaLynn M Williams; Andrea M Baran; Mahlon Schaffer; Jocelyn Bushart; Lynn Rich; Jeremiah Moore; Paul M Barr; Clive S Zent
Journal:  Am J Hematol       Date:  2019-11-03       Impact factor: 10.047

8.  The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.

Authors:  Max J Gordon; Andy Kaempf; Byung Park; Alexey V Danilov; Andrea Sitlinger; Geoffrey Shouse; Matthew Mei; Danielle M Brander; Tareq Salous; Brian T Hill; Hamood Alqahtani; Michael Choi; Michael C Churnetski; Jonathon B Cohen; Deborah M Stephens; Tanya Siddiqi; Xavier Rivera; Daniel Persky; Paul Wisniewski; Krish Patel; Mazyar Shadman
Journal:  Clin Cancer Res       Date:  2021-06-24       Impact factor: 12.531

9.  Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia.

Authors:  Hua-Jay J Cherng; Nitin Jain; Beenu Thakral; Tariq Muzzafar; Roberto N Miranda; Dongfeng Tan; Asif Rashid; Neda Kalhor; Andrew W Hahn; Lauren A Byers; Christine M Parseghian; Alessandra Ferrajoli; Naveen Pemmaraju
Journal:  Leuk Res       Date:  2020-09-13       Impact factor: 3.715

10.  Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.

Authors:  Christopher Pleyer; Clare Sun; Sanjal Desai; Inhye E Ahn; Xin Tian; Pia Nierman; Susan Soto; Jeanine Superata; Janet Valdez; Jennifer Lotter; Adrian Wiestner
Journal:  Leuk Lymphoma       Date:  2020-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.